A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer

NCT00001446 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

NIH

Sponsor class

Conditions

Prostatic Neoplasm

Interventions

DRUG: thalidomide

Sponsor

National Cancer Institute (NCI)